通过使用pH驱动方法对脂质体进行封装来提高醇的生物可用性
Yexuan Yao1, Li Ma1, Chengwei Yu2
1State Key Laboratory of Food Science and Resources, Nanchang University, No. 235 Nanjing East Road, Nanchang 330047, Jiangxi, China.
Food chemistry
|February 13, 2024
概括
新型铁醇脂质体 (Tyr-LPs) 的开发旨在增强铁醇.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 铁醇具有较差的水溶性和口服生物利用性.
- 需要有效的输送系统来提高醇的治疗潜力.
研究的目的:
- 开发和表征新的铁醇脂质体 (Tyr-LPs) 以改善口服输送.
- 评估Tyr-LPs的物理化学特性和体内药物动力学性能.
主要方法:
- 用pH驱动的方法制备封装铁醇的脂质体.
- 描述涉及福里埃变换红外光谱 (FTIR) 和X射线衍射 (XRD).
- 评估了物理化学特性,如分散性,不稳定性指数,多分散性指数 (PDI) 和封装效率 (EE).
- 在体内药理动力学研究比较了口服提洛索尔与Tyr-LPs.
主要成果:
- FTIR和XRD证实了在脂质体内的无形状态中成功封装铁醇.
- 在醇含量为1.33 mg/ml和Tyr:LP质量比为1:2的情况下,可以达到最佳的分散性.
- 优化的Tyr-LP配方显示不稳定性指数为0.049 ± 0.004,PDI为0.274 ± 0.003,EE为94.8 ± 2.5%. 这两种配方的不稳定性指数均为0.049 ± 0.004.
- 在体内研究表明,Tyr-LPs的AUC增加了1.5倍,Cmax增加了2.25倍,而Tyr-LPs的Tyr-LPs的Cmax增加了1.5倍,而Tyr-LPs的Cmax增加了2.25倍.
结论:
- 新型铁醇脂质体 (Tyr-LPs) 已成功制备,显著提高了铁醇的口服生物可用性.
- 优化的Tyr-LP配方提供了更好的分散性和封装效率.
- 这项研究为提洛的最佳口服输送提供了一个有前途的平台.
更多相关视频
相关概念视频
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
208
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
208
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
1.4K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
1.4K
Factors Influencing Bioavailability: First-Pass Elimination
6.4K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.4K


